



SUPPORT PROSPECTUS
2021 HCC-TAG CONFERENCE

THERAPEUTIC AGENTS FOR HEPATOCELLULAR CARCINOMA

TABLE OF CONTENTS

- 3 Executive Summary/Course Directors
- 4 Scientific Advisory Board Committee
- 5 Agenda
- 8 2021 HCC-TAG Support Opportunities and Important Deadlines
- 9 2021 HCC-TAG Conference Sponsorship Opportunities
- 11 2021 HCC-TAG Exhibit/Sponsor Information Form
- 12 Exhibitor Registration Instructions



EXECUTIVE SUMMARY

We are pleased to announce the second annual 2021 Hepatocellular Carcinoma-Therapeutic Agents (HCC-TAG) Conference, which will be held as a virtual conference March 26–27, 2021. We believe this live online interactive webinar format will provide an effective, engaging, and safe opportunity to learn from leading researchers about the latest innovative science on HCC. Online attendees will be able to engage in interactive discussions by sharing their insights with others on multiple topics related to advances in HCC therapeutic agent development and the diagnosis and management of patients with HCC. The HCC-TAG Conference's primary objective is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HCC. The goal of the HCC-TAG Conference is to bring together key opinion leaders from the teams of clinicians that care for patients with HCC (oncologists, hepatologists, gastroenterologists, interventional radiologists, surgeons) with the pharmaceutical industry to discuss optimized trial design, patient populations, therapeutic endpoints, and the potential benefits these agents can have for patients with HCC. We believe the goal of this conference will be accomplished by delivering a focused scientific educational update that highlights the most clinically relevant advances in HCC to guide future directions in diagnostic procedures and therapeutic agent development for HCC. The course directors and the Scientific Advisory Council of HCC-TAG, an internationally renowned group of academic researchers at the forefront of HCC therapeutic development, will provide comprehensive strategic planning and guidance for the educational program. These renowned experts will assist in the development of the educational content and will serve as faculty at the conference. They will address the latest clinical trial results, design updates, new pharmacological updates, and the pharmacoeconomic benefit of future treatment to the healthcare system. In addition, the faculty will focus on epidemiology, comorbidities associated with this disease, and the impact of HCC (natural history).

COURSE DIRECTORS



Michael Charlton, MD, MBBS, FRCP

Professor of Medicine
University of Chicago
Chicago, IL



Anthony El-Khoueiry, MD

Associate Professor of Clinical Medicine
Phase I Program Director
Director of Clinical Investigations Support Office
USC Norris Comprehensive Cancer Center
Los Angeles, CA



Julie K. Heimbach, MD

Surgical Director of Liver Transplantation
Mayo Clinic College of Medicine and Science
Rochester, MN



Anjana Pillai, MD

Associate Professor of Medicine
Medical Director, Liver Tumor Program
Medical Director, Adult Living Donor
Liver Transplant Program
Center for Liver Diseases
University of Chicago Medicine
Chicago, IL



Riad Salem, MD, MBA

Professor of Radiology, Medicine, and Surgery
Chief, Section of Vascular and
Interventional Radiology
Vice Chairman, Image-Guided Therapy
Department of Radiology
Northwestern University
Chicago, IL



Amit Singal, MD, MS

David Bruton Jr. Professor in
Clinical Cancer Research
Associate Professor of Medicine
Medical Director of Liver Tumor Program
Clinical Chief of Hepatology
University of Texas Southwestern
Dallas, TX

SCIENTIFIC ADVISORY BOARD COMMITTEE

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, NY

Vatche Agopian, MD
David Geffen School of Medicine at UCLA
Los Angeles, CA

George Behrens, MD
Vascular & Interventional Radiology
Hinsdale, IL

Mitesh Borad, MD
Mayo Clinic
Phoenix, AZ

Rich Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, CA

Karim Halazun, MD, FACS
Weill Cornell Medicine
New York, NY

Matthew Johnson, MD
Indiana University–Purdue University Indianapolis
Indianapolis, IN

Sunil Krishnan, MD, FACP
MD Anderson Cancer Center
Houston TX

Laura Kulik, MD
Northwestern University Feinberg School of Medicine
Chicago, IL

Robert Lewandowski, MD, FSIR
Northwestern University Feinberg School of Medicine
Chicago, IL

Neil Mehta, MD
University of California, San Francisco
San Francisco, CA

Neehar Parikh, MD, MS
Michigan Medicine
Ann Arbor, MI

David Pinato, MD, PhD
Imperial College
London, United Kingdom

Nicole Rich, MD
UT Southwestern Medical Center
Dallas, TX

Lewis Roberts, MB, CHB, PHD
Mayo Clinic
Rochester, MN

Augusto Villaneuva Rodriguez, MD, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Reena Salgia, MD
Henry Ford Health System
Detroit, MI

Gonzalo Sapisochin, MD
University of Toronto
Toronto, ON

For an updated list of faculty/speakers, please visit our website:

WWW.HCC-TAG.ORG

Conference management services provided by:

Focus Medical Communications

2021 AGENDA*

(Times in Mountain Standard Time)

FRIDAY, MARCH 26, 2021

7:25–7:55 AM Virtual Exhibit

7:55–8:05 AM Welcome
Anjana Pillai, MD – University of Chicago Medicine (Chicago, Illinois)
Michael Charlton, MD, MBBS – University of Chicago Medicine (Chicago, Illinois)

8:05–8:25 AM The Year 2020 in Review
Anjana Pillai, MD – University of Chicago Medicine (Chicago, Illinois)

8:30–9:30 AM THE PATIENT JOURNEY 1

CASE #1: EARLY TO INTERMEDIATE HCC

Moderator *Amit Singal, MD, MS – University of Texas Southwestern Medical Center (Dallas, Texas)*

Presenters *Karim Halazun, MD, FACS – Weill Cornell Medicine (New York, New York)*

Neil Mehta, MD – University of California San Francisco (San Francisco, California)

Lipika Goyal, MD – Massachusetts General Hospital (Boston, Massachusetts)

Robert Lewandowski, MD – Northwestern University Feinberg School of Medicine (Chicago, Illinois)

Discussion

9:30–10:30 AM THE PATIENT JOURNEY 2

CASE #2: INTERMEDIATE TO ADVANCED HCC

Moderator *Catherine Frenette, MD – Scripps MD Anderson Cancer Center (La Jolla, California)*

Presenters *Laura Kulik, MD – Northwestern University Feinberg School of Medicine (Chicago, Illinois)*

Gagandeep Brar, MD – Weill Cornell Medicine/NewYork-Presbyterian Hospital (New York, New York)

Vatche G. Agopian, MD – The Dumont–UCLA Liver Cancer Center (Los Angeles, California)

Beau Toskich, MD – Mayo Clinic, Jacksonville (Jacksonville, Florida)

Discussion

10:30–11:00 AM Virtual Exhibit

11:00 AM–12:20 PM UPDATES ON SYSTEMIC THERAPY

Moderators *Richard Finn, MD – David Geffen School of Medicine at UCLA (Los Angeles, California)*
Ghassan Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center (New York, New York)

11:00–11:20 AM First-Line Therapies
Anthony El-Khoueiry, MD – University of Southern California (Los Angeles, California)

*Subject to change

2021 AGENDA (CONTINUED) *(Times in Mountain Standard Time)*

11:20–11:40 AM Role of IO (Beyond Advanced HCC)
David Pinato, MD – Imperial College London (London – United Kingdom)

11:40 AM–12:00 PM Sequencing Systemic Therapy: Second Line and Beyond
Mark Yarchoan, MD – Johns Hopkins (Baltimore, Maryland)

12:00–12:20 PM Discussion

12:20–1:20 PM ORAL PRESENTATIONS WITH EXPERT COMMENTARY

Moderators
Tim Meyer, MD – UCL Cancer Institute, University College London (London, United Kingdom)
Julie Heimbach, MD – Mayo Clinic, Rochester (Rochester, Minnesota)

12:20–12:35 PM Oral Presentation #1 – Study 22: A Randomized, Phase 2 Trial of Durvalumab and Tremelimumab in Advanced HCC
Katie Kelley, MD – University of California San Francisco (San Francisco, California)

12:35–12:50 PM Discussion

12:50–1:05 PM Oral Presentation #2 – Living Donor Liver Transplantation for HCC: Pros and Cons
Gonzalo Sapisochin, MD – University of Toronto (Toronto, Canada)

1:05–1:20 PM Discussion

1:20–1:30 PM Closing Remarks and Updates for Day #2
Anjana Pillai, MD – University of Chicago Medicine (Chicago, Illinois)

1:30–2:00 PM Virtual Exhibit

SATURDAY, MARCH 27, 2021 *(Times in Mountain Standard Time)*

7:30–8:00 AM Virtual Exhibit

8:00–9:50 AM DEBATES

Moderators
Anjana Pillai, MD – University of Chicago Medicine (Chicago, Illinois)
Riad Salem, MD, MBA – Northwestern University Medical Center (Chicago, Illinois)

8:00–8:30 AM Case #1: Treatment of BCLC B
Edward Kim, MD – Mount Sinai Health Systems (New York, New York)
Richard Finn, MD – David Geffen School of Medicine at UCLA (Los Angeles, California)

8:30–8:45 AM Discussion

8:45–9:05 AM Case #2: To Baveno or NOT in the IMBrave World
Neehar Parikh, MD – University of Michigan (Ann Arbor, Michigan)
Reena Salgia, MD – Henry Ford Health System (Detroit, Michigan)

9:05–9:15 AM Discussion

9:20–9:40 AM Case #3: UNOS Bridging to LT – IO or LRT
Parissa Tabrizian, MD – Mount Sinai Health Systems (New York, New York)
Riad Salem, MD, MBA – Northwestern University Medical Center (Chicago, Illinois)

2021 AGENDA (CONTINUED) *(Times in Mountain Standard Time)*

9:40–9:50 AM Discussion

10:00 AM–12:15 PM EMERGING THERAPIES

Moderators

Lewis R. Roberts, MB, CHB, PhD – Mayo Clinic, Rochester (Rochester, Minnesota)
Anthony El-Khoueiry, MD – University of Southern California (Los Angeles, California)

10:00–10:15 AM HCC Radiomics: Present and Future
Claude B. Sirlin, MD – University of California San Diego (La Jolla, California)
Kathryn Fowler, MD – University of California San Diego Health (San Diego, California)

10:20–10:35 AM Biomarker Development
Augusto Villanueva, MD, PhD – Icahn School of Medicine at Mount Sinai (New York, New York)

10:35–10:45 AM Discussion

10:45–11:15 AM Virtual Exhibit

EMERGING THERAPIES

Moderators

Lewis R. Roberts, MB, CHB, PhD – Mayo Clinic, Rochester (Rochester, Minnesota)
Augusto Villanueva, MD, PhD – Icahn School of Medicine at Mount Sinai (New York, New York)

11:15–11:35 AM Early Phase Therapeutics for Advanced HCC: Combinations and Post IO
Mitesh J. Borad, MD – Mayo Clinic, Phoenix (Phoenix, Arizona)

11:35–11:50 AM Cellular Therapies
Tim F. Greten, MD – National Cancer Institute (Bethesda, Maryland)

11:50 AM–12:05 PM Histotripsy
Mishal Mendiratta-Lala, MD – University of Michigan School of Medicine (Ann Arbor, Michigan)

12:05–12:15 PM Discussion

12:15–1:15 PM ORAL PRESENTATIONS WITH EXPERT COMMENTARY

Moderators

Riad Salem, MD, MBA – Northwestern University Medical Center (Chicago, Illinois)
Karim Halazun, MD, FACS – Weill Cornell Medicine (New York, New York)

12:15–12:30 PM Oral Presentation #1 – Overall survival is more than double in locally advanced HCCs with SIRT and personalized dosimetry: The DOSISPHERE-01 Study
Etienne Garin, MD – Université de Rennes (Rennes, France)

12:30–12:45 PM Discussion

12:45–1:00 PM Oral Presentation #2 – Open-label neoadjuvant randomized study of Nivolumab versus Nivolumab plus Ipilimumab in patients with resectable HCC
Ahmed Omar Kaseb, MD, CMQ – The University of Texas - Anderson Cancer Center (Houston, Texas)

1:00–1:15 PM Discussion

1:15–1:30 PM Closing Remarks
Anjana Pillai, MD – University of Chicago Medicine (Chicago, Illinois)

1:30–2:00 PM Virtual Exhibit

2021 HCC-TAG SUPPORT OPPORTUNITIES AND IMPORTANT DEADLINES

SUPPORT OPPORTUNITIES

The HCC-TAG Conference offers different levels of sponsorship to support the needs of the healthcare professionals who will attend the conference.

HCC-TAG CONFERENCE DATES

March 26–27, 2021

Virtual Conference

IMPORTANT DEADLINES

Initial Agreement: Supporters showing interest must commit in writing by completing the “Support Opportunities” form found on the last page of this prospectus.

Payment: If requested, invoices can be generated on receipt of the fully executed Letter of Agreement, with payment due 60 days from the date of the signed Letter of Agreement. Please include a copy of the invoice and/or purchase order with payment.

Checks should be made payable to:
Focus Medical Communications

Remit payment to:
Focus Medical Communications
Attn: HCC-TAG
7 Century Drive, Suite 104
Parsippany, NJ 07054

SPONSORSHIP OPPORTUNITIES

The HCC-TAG Conference has designed a comprehensive and multi-tiered corporate sponsorship program that provides benefits at every level. We are excited to announce new annual corporate sponsorship packages for the Diamond, Platinum, and Gold levels. These packages are designed for companies and organizations interested in supporting HCC-TAG on an annual basis. As a corporate sponsor, your company will be listed as a main contributor on the HCC-TAG website.

DIAMOND: \$75,000

At the HCC-TAG Virtual Conference:

- Acknowledgment as Diamond sponsor on individual conference websites and all conference materials
- Recognition as Diamond sponsor with logo placement on the HCC-TAG Conference opening remarks on conference PowerPoints + verbal recognition
- Ten (10) complementary conference registrations for the virtual conference
- Executive board exchange: Opportunity to meet with HCC-TAG course directors via Zoom meeting.
*The meeting to be scheduled during non-conference hours**
- Faculty meeting clinical exchange: The opportunity to meet for **one hour (1)** via a virtual meeting with up to eight (8) faculty members.†
- Access to select HCC-TAG faculty interviews. Content and presentations for distribution by your company and/or your educational partner (Onclive).
- Plenary platform: The opportunity to give a five (5) minute presentation to audience before morning or afternoon break. (Can be a presentation or a video).
- Additional promotional reach opportunity: Two (2) company announcements distributed via email and social media communicating your company's message to the full HCC-TAG membership and other followers.
- Virtual exhibit booth for online conference^Δ

GOLD: \$18,000

At the HCC-TAG Virtual Conference:

- Acknowledgment as Gold Sponsor on individual conference websites and all conference materials
- Recognition as Gold sponsor with logo placement on the HCC-TAG Conference opening remarks on conference PowerPoints + verbal recognition
- Four (4) complementary conference registrations for virtual conference
- Faculty meeting clinical exchange: The opportunity to meet for **one hour (1)** via a virtual meeting with up to four (4) faculty members.†
- Additional promotional reach opportunity: One (1) company announcement distributed via email and social media communicating your company's message to the full HCC-TAG membership and other followers.
- Exhibit booth for virtual conference^Δ

† The executive board exchange and the faculty meeting clinical exchange can be arranged either on Friday or on Saturday after 1:30 PM. Arrangements can also be made for a time and date post HCC-TAG. (First come first served – Priority will be given to top-tier sponsors).

* For the virtual meeting, HCC-TAG will provide the Zoom platform.

PLATINUM: \$37,000

At the HCC-TAG Virtual Conference:

- Acknowledgment as Platinum sponsor on individual conference websites and all conference materials
- Recognition as Platinum sponsor with logo placement on the HCC-TAG Conference opening remarks on conference PowerPoints + verbal recognition
- Six (6) complementary conference registrations for the virtual conference
- Faculty meeting clinical exchange: The opportunity to meet for **one hour (1)** via a virtual meeting with up to six (6) faculty members.†
- Plenary platform: The opportunity to give a five (5) minute presentation to audience before morning or afternoon break. (Can be a presentation or a video).
- Additional promotional reach opportunity: One (1) company announcement distributed via email and social media communicating your company's message to the full HCC-TAG membership and other followers.
- Virtual exhibit booth for virtual conference^Δ

CONFERENCE SPONSOR: \$5,000

At the HCC-TAG Virtual Conference:

- Acknowledgment as a Conference Sponsor on individual conference websites and all conference materials
- Two (2) complementary registrations
- Exhibit booth for virtual conference^Δ

SPONSORSHIP OPPORTUNITIES (CONTINUED)

Virtual booth optional items are for Diamond, Platinum, and Gold level sponsors:

△ The virtual booth will contain the following optional items:

- Company overview – One (1) brief paragraph introducing your company, products, or services
- Company website (link or a product link)
- Optional: Images or video content
 - Image: 8MB max, high res, 600 x 315 minimum – JPEG or PNG
 - Video: Link (YouTube, etc.) or file no larger than 15GB
 - avi, .mpeg, .mpg, .mpe, .mp4, .mkv, .webm, .mov, .ogv, .vob, .m4v, .3gp, .divx, .xvid, .mxf, .wmv
- Corporate or product logo – PNG/JPEG format
- Company representative(s) contact information
 - Name
 - Headshot
 - Phone
 - Email
 - Social links (LinkedIn, Facebook, Twitter, Instagram, YouTube, Zoom, etc.)
- PDF document – Promotional piece to be uploaded to sponsor

To discuss conference support opportunities further, please contact:

Pablo Gabella

Sr. Director, Business Development
Focus Medical Communications

Tel: 714-869-2769

pgabella@focusmeded.com

2021 HCC-TAG EXHIBIT

SPONSOR INFORMATION FORM

TO SECURE YOUR SPONSORSHIP,
CLICK HERE
TO COMPLETE THE ONLINE FORM AND AGREEMENT

Checks should be made payable to:

Focus Medical Communications
(Tax ID 20-8216514)

Remit payment to:

Focus Medical Communications

Attn: HCC-TAG

7 Century Drive, Suite 104
Parsippany, NJ 07054

EXHIBITOR REGISTRATION INSTRUCTIONS

Your exhibit space is contingent on full payment. All additional requests (e.g., power source, internet access) will be handled between the exhibitor and the hotel. The costs will be charged directly to the exhibitor.

CANCELLATION POLICY

- A refund, less a handling fee of 10%, will be given for cancellations received in writing within three (3) business days after the Sponsorship/Exhibitor's Agreement is completed using the online webform. After this date, no refunds will be granted unless the conference is cancelled altogether.
- If the conference is postponed and rescheduled within one (1) year of the originally scheduled date, no refunds will be granted. However, the sponsorship/exhibitor fee shall be applied to the rescheduled conference.
- Should the conference be cancelled and not take place within one (1) year of the originally scheduled date, a full refund shall be granted.

LIABILITY

The exhibitor agrees to protect, save, defend, and keep Focus Medical Communications, LLC, HCC-TAG, their agents, and their guests forever harmless from any damages or charges imposed by the negligence of the exhibitor and/ or any loss, cost, damage, liability, or expense that arises from the exhibitor's occupancy and/or use of the exhibit premises.

Signature: _____ Date: _____

Print Name: _____

For more information, please visit:

WWW.HCC-TAG.ORG

Follow us on Twitter!

@HCCTagConf